According to the IPO, I know that the company has been approved by the China Securities Regulatory Commission to register for the listing of Sino Medical, and there is only one foot left in the market. Source | This article is known by IPO
Editor’s note: This article is from WeChat public account “IPO knows early” (ID: ipozaozhidao) , author: Uncle C.
According to the IPO, I know that the company has been approved by the China Securities Regulatory Commission to register for the listing of Sino Pharmaceutical, and only one foot is left from the listing of the Science and Technology Board.
The total share capital of the company before the issuance was 360 million shares. Excluding the over-allotment, the public offering of this stock does not exceed 80 million shares. If the over-allotment option is exercised in full, the issue of shares will not exceed 92 million shares. Sino Medical plans to raise 280 million yuan for the high-end interventional device expansion project, R&D center construction project and supplementary liquidity.
Remove the red chip architecture and complete the listing of the board.
It is worth mentioning that there is a red-chip structure in Sino Medical. In order to eliminate the red chip structure and achieve asset, business and financial integrity, Sino Intune acquired 100% equity of Fuki Sunshine and Anwar Henderson in April 2017 and acquired Beijing Sinoman 100 in April 2018. % of the company’s US-based company, Nova Vascular Inc., absorbed the US company Nova Vascular LLC. in November 2017. The company’s Hong Kong subsidiary, Pioneer Technology (now renamed Sinono), acquired Alchi in June 2018. 100% equity of Medics. According to the prospectus, the company has a total of 27 shareholders, the controlling shareholder is Weixin Sunshine, holding 90,902,330 shares of the company, accounting for 25.25% of the total share capital.
Main coronary stents,The main product is single, more products are under research
The coronary stent isA branch of the heart disease device market. Coronary stent is a traditional medical device used in percutaneous coronary intervention (PCI) through a conventional balloon dilatation catheter. It is a common medical device used in percutaneous coronary intervention (PCI). Due to the small trauma and good effect, PCI has become one of the main methods for the treatment of cardiovascular stenosis.
In 2017, the number of PCI cases in China was 750,000, with an average of 542 patients per year for PCI. In the same period, more than 2,000 patients per 100,000 people in Japan received PCI, and more than 3,000 in the United States. It can be seen that the per capita PCI operation in China is still at a relatively low level compared with developed countries. However, the domestic PCI operation has achieved a compound growth rate of 16.09% in recent years, so the demand for domestic PCI is in a rapid release.
Sino Medical Prospectus disclosed that its BuMA drug stent has been verified by a large number of clinical applications, and the product has excellent handling performance, which is convenient for doctors to successfully complete the operation. The unique coating technology advantages of BuMA drug stent make the stent coating of this product have higher bonding strength, avoiding the problem of coating cracking during body insertion and release; at the same time, the drug can be completely released in 30 days, and the drug carrier can be in the body 6 Weekly degradation and absorption, which is the shortest time in the same kind of products, can reduce the inhibition and adverse effects of drugs and carriers on vascular endothelium repair under the condition of ensuring drug availability. The results of several clinical studies show that the safety advantage of this product is significant.
The results of the trial showed that the performance of BuMA products was significantly better than that of the control competing products in the late stage of postoperative lumen loss, stent trabecular coverage and stent thrombosis. The relevant research results were published in core journals at home and abroad. Papers. The BuMA biodegradable drug-coated coronary stent system was awarded the “National Key New Product” by the Ministry of Science and Technology in 2011 and the “Tianjin Killer Product” in 2014.
The research products cover a new generation of BuMA cardiac stents, fully degradable cardiac stents, intracranial vascular products, and mitral valve systems. In addition to China, the market covers the developed countries such as the United States, Europe, and Japan. In line with expectations, multiple core projects are expected to be approved for listing within 1-2 years, which will greatly enhance the company’s ability to continue operations.